Retatrutide, a groundbreaking dual-acting glucose-responsive incretin agent, represents a significant leap in peptide treatments for the treatment of type 2 sugar disorders and, increasingly, obesity. Unlike many existing treatment interventions, retatrutide merges the actions of a GLP-1 receptor stimulant and a GIP receptor agonist, offering a mor